Aenne Beer, VP Marketing and Sales Operations, Varian Radiation Oncology Solutions at Siemens Healthineers, shared on LinkedIn:
“First, TrueBeam. Now, Accela.
And between them, years of asking how we can do better for patients.
Universitätsspital Zürich has been part of our innovation journey for years, from welcoming the world’s first TrueBeam to becoming one of the first centers worldwide to introduce Accela.
Today in Zurich, that journey continued.
Together, we explored what it takes to turn a new generation of radiotherapy technology into meaningful clinical progress.
Besides the experts from Switzerland, partners from Italy, and Germany joined the dialogue. Leading institutions like Universitätsspital Zürich, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, or FAU Erlangen-Nürnberg bring far more than expertise.
They bring the questions, the clinical realities, and the courage to challenge what comes next.
My sincere thanks to Matthias Guckenberger, Stephanie Tanadini-Lang, Jonas Willmann, Riccardo Dal Bello, Maria Antonietta Gambacorta, Stefanie Corradini,
Christoph Bert, and the many teams contributing to this work.
The technology will continue to evolve. The relationships behind it are what give that progress direction.
The next chapter is ours to shape together. Its greatest promise belongs to the patients whose lives it may change.
CE Marked. 510(k) pending. Not available for sale in the U.S. and no guarantee of commercialization or feature availability.”
You may also be interested in:
Aenne Beer: Varian Introduces Accela in New Radiation Oncology Webinar
Dorin Comaniciu: Siemens Healthineers Wins Top Prize in China’s National Healthcare AI Contest
